NextCure closed a $21.5 million PIPE financing, extending cash runway beyond the first half of 2026.
Led by Ikarian Capital, Squadron Capital Management, Affinity Healthcare Fund, and Exome Asset Management.
Issued 708,428 shares of Common Stock at $8.52 per share.
Net proceeds to be used for general working capital needs and extending cash runway.
Focus on advancing ADC programs, SIM0505 (CDH6 ADC) and LNCB74 (B7-H4 ADC).
Gross Proceeds
Approximately $21.5 million raised in PIPE financing.
Placement Agent
H.C. Wainwright & Co. acted as the exclusive placement agent.
Use of Proceeds
Funds to be used for general working capital and extending cash runway.
ADC Programs
Focus on advancing two antibody drug conjugate programs, SIM0505 and LNCB74.
- The financing extends cash runway into the first half of 2027, providing stability for NextCure's developmental phases.
- This funding will support the completion of proofs of concept for key programs, highlighting the company's commitment to advancing cancer therapies.
NextCure's successful PIPE financing demonstrates investor confidence and provides a solid financial foundation for future growth and development.